 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Intra-Cellular Therapies, Inc. (ITCI) discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS).
Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia and bipolar depression, as well as to treat behavioral disturbances associated with dementia, sleep disturbances associated with neurologic and psychiatric disorders, sleep and behavioral disturbances associated with autism spectrum disorder, and depression and other mood disorders.
The company also develops ITI-002 phosphodiesterase type 1 (PDE1) program that is in phase I development for the treatment of central nervous system, cardiovascular, and other disorders; and PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases.
It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize its proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases.
Shares have formed a "Double Bottom" and higher share prices are expected for this stock. Note that on the last day of February one director purchased 100,000 shares on the open market. The expected market for ITI-007, if approved, could be around the $1.2 billion mark. The Company presented a paper last night in Florence, Italy titled “Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Efficacy Results from a Randomized, Double-Blind, Placebo-Controlled Trial.” Higher share prices are expected for this stok.
52-Weeks Trading Range: $19.86 - $60.79
Entry Point: $30.00
Stop Loss: $28.50
Target Price: $33.00
ITCI closed at $33.70. Note that we expect shares to continue their climb. If you elect to stay in the position, please raise your stop loss to $33.00.
